Mirae Asset Global Investments Co. Ltd. Has $11.12 Million Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 397.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 301,614 shares of the medical device company's stock after buying an additional 240,966 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 0.46% of Tandem Diabetes Care worth $11,121,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in TNDM. Bellevue Group AG lifted its holdings in shares of Tandem Diabetes Care by 19.9% during the 3rd quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company's stock valued at $78,496,000 after acquiring an additional 307,624 shares in the last quarter. MetLife Investment Management LLC grew its position in shares of Tandem Diabetes Care by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 37,422 shares of the medical device company's stock valued at $1,587,000 after buying an additional 21,086 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Tandem Diabetes Care by 134.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock valued at $8,379,000 after buying an additional 113,355 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in shares of Tandem Diabetes Care by 368.5% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 26,125 shares of the medical device company's stock valued at $1,108,000 after buying an additional 20,549 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Tandem Diabetes Care by 32.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 272,097 shares of the medical device company's stock valued at $11,540,000 after buying an additional 66,687 shares during the last quarter.

Tandem Diabetes Care Price Performance

Shares of NASDAQ:TNDM traded down $0.34 during trading on Monday, reaching $35.77. The company had a trading volume of 749,118 shares, compared to its average volume of 900,715. The firm's fifty day moving average is $35.42 and its 200 day moving average is $37.13. The firm has a market capitalization of $2.35 billion, a PE ratio of -18.57 and a beta of 1.32. Tandem Diabetes Care, Inc. has a twelve month low of $22.03 and a twelve month high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90.

Wall Street Analyst Weigh In

TNDM has been the subject of a number of recent research reports. Barclays boosted their price objective on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the company an "overweight" rating in a research report on Friday, November 8th. Morgan Stanley raised shares of Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and set a $45.00 price objective for the company in a research report on Monday, December 2nd. Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care in a research report on Wednesday, November 6th. They set an "outperform" rating and a $42.00 price objective for the company. Citigroup decreased their target price on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group decreased their target price on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a "buy" rating for the company in a research report on Thursday, November 7th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $53.81.

Insider Transactions at Tandem Diabetes Care

In related news, Director Kim D. Blickenstaff sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the director now owns 195,190 shares in the company, valued at approximately $5,855,700. This represents a 4.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.20% of the company's stock.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.